Company Filing History:
1 out of 33 
1 out of 2 Years Active: 2018
Title: Eva Kudova: Innovator in Neuroprotective Compounds
Introduction
Eva Kudova is a prominent inventor based in Praha, Czech Republic. She has made significant contributions to the field of neuroprotective compounds, focusing on innovative solutions for neuropsychiatric disorders. Her work is characterized by a commitment to advancing medical science and improving patient outcomes.
Latest Patents
Eva Kudova holds a patent for "Amphiphilic compounds with neuroprotective properties." This patent describes amphiphilic compounds with a tetradecahydrophenanthrene skeleton and their enantiomers, which exhibit neuroprotective effects. These compounds are utilized in methods for treating various neuropsychiatric disorders associated with an imbalance in the glutamatergic neurotransmitter system. The conditions addressed include ischemic damage to the central nervous system (CNS), neurodegenerative changes, affective disorders, depression, post-traumatic stress disorder, anxiety, schizophrenia, psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma, and related diseases. The patent also includes a pharmaceutical composition containing these compounds.
Career Highlights
Throughout her career, Eva has worked with esteemed institutions such as the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences and the Institute of Physiology of the Czech Academy of Sciences. Her research has been pivotal in the development of therapeutic strategies for complex neurological conditions.
Collaborations
Eva has collaborated with notable colleagues, including Hana Chodounska and Vojtech Kapras. Their combined expertise has contributed to the advancement of research in neuroprotective therapies.
Conclusion
Eva Kudova's innovative work in the field of neuroprotective compounds highlights her dedication to addressing critical health challenges. Her contributions are paving the way for new treatments that can significantly improve the quality of life for individuals suffering from neuropsychiatric disorders.